Linguistic Adaptation and Validation of the Spanish Version of the Benign Prostatic Hyperplasia-Patient Impact Measure (BPH-PIM ® )

Author： Llorente Carlos  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.26, Iss.2, 2006-01, pp. : 103-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Photochemotherapy therapy with lemuteporfin is safe and may be active in benign prostatic hyperplasia (BPH)

By  

Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Diagnosis and treatment recommendations for benign prostatic hyperplasia (BPH) have been released by the American Urological Association (AUA) Practice Guidelines Committee.

By  

Inpharma, Vol. 1, Iss. 1410, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Diagnosis and treatment recommendations for benign prostatic hyperplasia (BPH) have been released by the American Urological Association (AUA) Practice Guidelines Committee.

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 436, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treatment options for benign prostatic hyperplasia

By Thurlow R.J.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 225-246

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher   Kapoor Anil  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite